An integrative view of serpins in health and disease: the contribution of SerpinA3
A Sánchez-Navarro, I González-Soria… - … of Physiology-Cell …, 2021 - journals.physiology.org
Serpins are a superfamily of proteins characterized by their common function as serine
protease inhibitors. So far, 36 serpins from nine clades have been identified. These proteins …
protease inhibitors. So far, 36 serpins from nine clades have been identified. These proteins …
CD64: an attractive immunotherapeutic target for M1-type macrophage mediated chronic inflammatory diseases
OA Akinrinmade, S Chetty, AK Daramola, M Islam… - Biomedicines, 2017 - mdpi.com
To date, no curative therapy is available for the treatment of most chronic inflammatory
diseases such as atopic dermatitis, rheumatoid arthritis, or autoimmune disorders. Current …
diseases such as atopic dermatitis, rheumatoid arthritis, or autoimmune disorders. Current …
Critical issues in the development of immunotoxins for anticancer therapy
JS Kim, SY Jun, YS Kim - Journal of pharmaceutical sciences, 2020 - Elsevier
Immunotoxins (ITs) are attractive anticancer modalities aimed at cancer-specific delivery of
highly potent cytotoxic protein toxins. An IT consists of a targeting domain (an antibody …
highly potent cytotoxic protein toxins. An IT consists of a targeting domain (an antibody …
Recombinant immunotoxins development for HER2-based targeted cancer therapies
R Mahmoudi, H Dianat-Moghadam… - Cancer cell …, 2021 - Springer
Understanding the molecular mechanisms of cancer biology introduces targeted therapy as
a complementary method along with other conventional therapies. Recombinant …
a complementary method along with other conventional therapies. Recombinant …
Proteases as activators for cytotoxic prodrugs in antitumor therapy
UH Weidle, G Tiefenthaler… - Cancer genomics & …, 2014 - cgp.iiarjournals.org
Proteases are often overexpressed in tumor cells and/or the stromal compartment and can
thus be exploited in tumor therapy to activate cytotoxic prodrugs as, for example, in cytolytic …
thus be exploited in tumor therapy to activate cytotoxic prodrugs as, for example, in cytolytic …
Dual roles of granzyme B
H Wang, Y Huang, J He, L Zhong… - Scandinavian Journal of …, 2021 - Wiley Online Library
Granzyme B (GZMB) was first identified as a factor that could eliminate cells such as tumour
cells and bacteria/virus‐infected cells. However, comprehensive studies conducted on …
cells and bacteria/virus‐infected cells. However, comprehensive studies conducted on …
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous …
M Amoury, K Kolberg, AT Pham, D Hristodorov… - Cancer letters, 2016 - Elsevier
Triple-negative breast cancer (TNBC) is associated with poor prognosis and high
prevalence among young premenopausal women. Unlike in other breast cancer subtypes …
prevalence among young premenopausal women. Unlike in other breast cancer subtypes …
Human granzyme B based targeted cytolytic fusion proteins
P Hlongwane, N Mungra, S Madheswaran… - Biomedicines, 2018 - mdpi.com
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the
damage to healthy tissues. Controlled delivery of plant, bacterial and human toxins or …
damage to healthy tissues. Controlled delivery of plant, bacterial and human toxins or …
A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth …
J Niesen, G Hehmann-Titt, M Woitok, R Fendel, S Barth… - Cancer letters, 2016 - Elsevier
Human cytolytic fusion proteins (hCFPs) offer a promising immunotherapeutic approach for
the treatment of solid tumors, avoiding the immunogenicity and undesirable side-effects …
the treatment of solid tumors, avoiding the immunogenicity and undesirable side-effects …
Improving the therapeutic potential of human granzyme B for targeted cancer therapy
G Hehmann-Titt, S Schiffer, N Berges, G Melmer… - Antibodies, 2013 - mdpi.com
Conventional cancer treatments lack specificity and often cause severe side effects.
Targeted therapeutic approaches are therefore preferred, including the use of immunotoxins …
Targeted therapeutic approaches are therefore preferred, including the use of immunotoxins …